These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34925346)

  • 1. Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor.
    Desole C; Gallo S; Vitacolonna A; Vigna E; Basilico C; Montarolo F; Zuppini F; Casanova E; Miggiano R; Ferraris DM; Bertolotto A; Comoglio PM; Crepaldi T
    Front Immunol; 2021; 12():775151. PubMed ID: 34925346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
    Merchant M; Ma X; Maun HR; Zheng Z; Peng J; Romero M; Huang A; Yang NY; Nishimura M; Greve J; Santell L; Zhang YW; Su Y; Kaufman DW; Billeci KL; Mai E; Moffat B; Lim A; Duenas ET; Phillips HS; Xiang H; Young JC; Vande Woude GF; Dennis MS; Reilly DE; Schwall RH; Starovasnik MA; Lazarus RA; Yansura DG
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):E2987-96. PubMed ID: 23882082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the HGF receptor c-met by macrophages in experimental autoimmune encephalomyelitis.
    Moransard M; Sawitzky M; Fontana A; Suter T
    Glia; 2010 Apr; 58(5):559-71. PubMed ID: 19941340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met.
    Basilico C; Arnesano A; Galluzzo M; Comoglio PM; Michieli P
    J Biol Chem; 2008 Jul; 283(30):21267-77. PubMed ID: 18495663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.
    van der Horst EH; Chinn L; Wang M; Velilla T; Tran H; Madrona Y; Lam A; Ji M; Hoey TC; Sato AK
    Neoplasia; 2009 Apr; 11(4):355-64. PubMed ID: 19308290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.
    Park H; Kim D; Kim E; Sa JK; Lee HW; Yu S; Oh J; Kim SH; Yoon Y; Nam DH
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
    Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
    Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
    Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Sema domain of Met is necessary for receptor dimerization and activation.
    Kong-Beltran M; Stamos J; Wickramasinghe D
    Cancer Cell; 2004 Jul; 6(1):75-84. PubMed ID: 15261143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
    Michieli P; Basilico C; Pennacchietti S; Maffè A; Tamagnone L; Giordano S; Bardelli A; Comoglio PM
    Oncogene; 1999 Sep; 18(37):5221-31. PubMed ID: 10498872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A receptor-antibody hybrid hampering MET-driven metastatic spread.
    Modica C; Basilico C; Chiriaco C; Borrelli N; Comoglio PM; Vigna E
    J Exp Clin Cancer Res; 2021 Jan; 40(1):32. PubMed ID: 33446252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor.
    Yamamoto BJ; Elias PD; Masino JA; Hudson BD; McCoy AT; Anderson ZJ; Varnum MD; Sardinia MF; Wright JW; Harding JW
    J Pharmacol Exp Ther; 2010 Apr; 333(1):161-73. PubMed ID: 20086056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte growth factor and Met in drug discovery.
    Sakai K; Aoki S; Matsumoto K
    J Biochem; 2015 May; 157(5):271-84. PubMed ID: 25770121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four individually druggable MET hotspots mediate HGF-driven tumor progression.
    Basilico C; Hultberg A; Blanchetot C; de Jonge N; Festjens E; Hanssens V; Osepa SI; De Boeck G; Mira A; Cazzanti M; Morello V; Dreier T; Saunders M; de Haard H; Michieli P
    J Clin Invest; 2014 Jul; 124(7):3172-86. PubMed ID: 24865428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression.
    Lee BS; Kang S; Kim KA; Song YJ; Cheong KH; Cha HY; Kim CH
    Cell Death Dis; 2014 Apr; 5(4):e1159. PubMed ID: 24722284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis.
    Stabile LP; Rothstein ME; Keohavong P; Jin J; Yin J; Land SR; Dacic S; Luong TM; Kim KJ; Dulak AM; Siegfried JM
    Mol Cancer Ther; 2008 Jul; 7(7):1913-22. PubMed ID: 18645002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
    Kwon Y; Smith BD; Zhou Y; Kaufman MD; Godwin AK
    Oncogene; 2015 Jan; 34(2):144-53. PubMed ID: 24362531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling.
    Kirchhofer D; Yao X; Peek M; Eigenbrot C; Lipari MT; Billeci KL; Maun HR; Moran P; Santell L; Wiesmann C; Lazarus RA
    J Biol Chem; 2004 Sep; 279(38):39915-24. PubMed ID: 15218027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte growth factor in physiology and infectious diseases.
    Imamura R; Matsumoto K
    Cytokine; 2017 Oct; 98():97-106. PubMed ID: 28094206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain.
    DiCara DM; Chirgadze DY; Pope AR; Karatt-Vellatt A; Winter A; Slavny P; van den Heuvel J; Parthiban K; Holland J; Packman LC; Mavria G; Hoffmann J; Birchmeier W; Gherardi E; McCafferty J
    Sci Rep; 2017 Aug; 7(1):9000. PubMed ID: 28827556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.